Company: STAA
Filing Date: 2025-10-08
Form Type: DFAN14A
Source: 0001213900-25-097463
Chunk: 5

Company: STAAR SURGICAL CO
Filing Date: 2025-10-08
Form: DFAN14A
Chunk 5
---
1

(888) 368-0379

Media Contacts

Scott Deveau / Jeremy Jacobs

August Strategic Communications

Broadwood@AugustCo.com

(323) 892-5562

<div align='center'>3</div>

Exhibit 2

<div align='center'>Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “ AGAINST” Sale to Alcon

Glass Lewis Highlights Numerous Concerns Regarding the Sale Process, Timing, and Price

Confirms CEO and Chair Did Not Disclose Information to the Rest of the Board About Inbound Interest in Acquiring the Company

Finds STAAR Shareholders Would Be Better Served by Rejecting the Proposed Merger</div>

New York--(BUSINESS WIRE)--Broadwood Partners,
L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”),
a leading independent proxy advisory firm, has recommended that the shareholders of STAAR Surgical Company (“STAAR” or the
“Company”) (NASDAQ: STAA) vote “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”)
(NYSE: ALC) on the terms announced on August 5, 2025.

“Glass Lewis’s recommendation and
findings underscore our strong belief that STAAR conducted a highly questionable sale process that resulted in an ill-timed deal that
significantly undervalues the Company and its compelling prospects. We are confident that better alternatives exist than this deeply flawed
and short-sighted transaction,” said Neal C. Bradsher, Broadwood Founder and President.

“STAAR’s representatives admitted
during their meeting with Glass Lewis that CEO Steve Farrell and Chair Dr. Elizabeth Yeu did not disclose pertinent information to the
remainder of the Board about inbound interest to acquire the Company. As Glass Lewis notes, this inbound interest also was not disclosed
to shareholders in STAAR’s proxy statement. This is deeply concerning and strengthens our view that the process was poorly conducted,
and the outcome was conflicted and predetermined. The Board did not fulfill its fiduciary duty to maximize shareholder value because it
did not conduct a full and fair sale process designed to maximize the price.”

Shareholders representing more than 34% of STAAR’s
outstanding common shares – including Yunqi Capital, Defender Capital, CalSTRS, and former STAAR CEO David Bailey – have already
made public their opposition to the proposed transaction.